Niedrobnokomórkowy rak płuca – postępy w leczeniu

Maciej Krzakowski

Summary
Non-small cell lung cancer (NSCLC) still remains a major challenge – in Poland approximately 16 000 patients are diagnosed yearly. The 5-year survival rates have improved slowly over the last decade, but still only about 10% of NSCLC patients in Poland have a chance to survive 5 years. Surgery remains a treatment of choice in early stage NSCLC. The improvement in locally advanced stages is related to advances in combined modality therapy with the use of radiotherapy (RTH) and chemotherapy (CTH). The results of studies in the 1990s have demonstrated the role of palliative CTH in stage IV NSCLC. Further progress in the management of NSCLC could be due to the use of combined therapy in early stages of disease and to the development of molecularly targeted therapeutic modalities.

To jest tylko fragment artykułu. Aby przeczytać całość, przejdź do Czytelni medycznej.